In this article, we will list the 5 Best Fast Growth Stocks to Invest In Now. Please visit 10 Best Fast Growth Stocks to Invest In Now if you would like to see the extended list and the methodology behind it.
5. CoStar Group, Inc. (NASDAQ:CSGP)
On April 14, 2026, BTIG analyst Jake Fuller lowered the price target on CoStar Group, Inc. (NASDAQ:CSGP) to $55 from $60 and maintained a Buy rating as part of a Q1 preview in residential real estate. Jake Fuller said the firm is pushing out expectations for a recovery in existing home sales and noted a less favorable setup, with a cloudy outlook expected to weigh on 2026 expectations.
Similarly, Stephens analyst Brett Huff lowered the price target on CoStar Group, Inc. (NASDAQ:CSGP) to $50 from $70 and kept an Overweight rating following a Reuters report that activist Third Point exited its position and dropped its proxy fight. Brett Huff said the move reflected lower confidence in the core business but added that the impact of earlier activist efforts remains “nonetheless a positive.”
Earlier, Reuters reported that Third Point will not pursue a proxy fight against CoStar Group after concluding that efforts to push the company to refocus on its core business may not be sufficient to improve performance. Daniel Loeb said, “We no longer believe that our original thesis holds true today and have disposed of our position in its entirety.”
CoStar Group, Inc. (NASDAQ:CSGP) provides information, analytics, and online marketplace services to real estate and related business communities globally.
4. The Estée Lauder Companies Inc. (NYSE:EL)
On April 21, 2026, The Estée Lauder Companies Inc. (NYSE:EL) hired J.P. Morgan to arrange a financing package of around €5B ($5.89B) to support a takeover bid for Puig. The companies said last month they were exploring a combination that would bring brands such as Tom Ford, Carolina Herrera, Rabanne, Jean Paul Gaultier, and Clinique under one group to form the largest premium beauty player.
On April 16, 2026, JPMorgan lowered its price target on The Estée Lauder Companies Inc. (NYSE:EL) to $98 from $121 and maintained an Overweight rating, while removing the stock from its Analyst Focus List ahead of earnings. The firm cited a growing number of announced and potential deals as reducing visibility, but said the current valuation still presents an attractive entry point.
Earlier in April, BofA lowered its price target on The Estée Lauder Companies Inc. (NYSE:EL) to $120 from $130 and kept a Buy rating after the company confirmed discussions with Puig. The firm noted upcoming results from Puig on April 28 and Estee Lauder on May 1 could provide further detail on a potential transaction, and estimates a 100% equity deal would be about 25% EPS accretive at current share levels.
The Estée Lauder Companies Inc. (NYSE:EL) manufactures, markets, and sells skin care, makeup, fragrance, and hair care products worldwide.
3. Jazz Pharmaceuticals plc (NASDAQ:JAZZ)
On April 19, 2026, Barclays analyst Etzer Darout raised the price target on Jazz Pharmaceuticals plc (NASDAQ:JAZZ) to $225 from $224 and maintained an Overweight rating on the shares as part of a Q1 preview across the small and mid-cap biotechnology group.
Earlier in April, Raymond James resumed coverage of Jazz Pharmaceuticals plc (NASDAQ:JAZZ) with an Outperform rating and a $227 price target, saying the story has moved beyond the “it looks inexpensive/fairly valued, but where can I get upside?” view, citing improved visibility into the tail value of the Epidiolex franchise and “highly competitive” data from zanidatamab in gastroesophageal adenocarcinoma.
Last month, Piper Sandler raised its price target on Jazz Pharmaceuticals plc (NASDAQ:JAZZ) to $232 from $219 and maintained an Overweight rating, noting the company trades at about seven times EV/2026E EBITDA while offering visibility into double-digit top-line growth starting in 2027. The firm added that while competition around the oxybate franchise remains a factor, it does not expect it to materially affect the company’s overall growth outlook.
Jazz Pharmaceuticals plc (NASDAQ:JAZZ) develops and commercializes pharmaceutical products across the United States, Europe, and international markets.
2. NETSTREIT Corp. (NYSE:NTST)
On April 21, 2026, Cantor Fitzgerald raised its price target on NETSTREIT Corp. (NYSE:NTST) to $24 from $22 and maintained an Overweight rating. The firm said the company’s investment outlook is improving, pointing to higher net investment guidance of $400M–$600M and a pipeline that appears fully funded. While AFFO guidance increases are partly offset by dilution from equity issuance, Cantor Fitzgerald noted the portfolio remains fully leased with no notable credit issues, supporting a constructive setup and potential for further upside revisions.
Similarly, Stifel raised its price target on NETSTREIT Corp. (NYSE:NTST) to $22.25 from $21 and kept a Buy rating following Q1 results that came in line with its estimates.
On April 19, 2026, NETSTREIT reported Q1 AFFO of 34c, matching the 34c consensus estimate. Mark Manheimer said the company delivered a “strong start to the year” with a record level of net investments, citing disciplined sourcing and underwriting alongside an attractive acquisitions market. Mark Manheimer also noted that a strengthened balance sheet, supported by $314M of gross forward equity sales, led to increases in both 2026 net investment guidance and the midpoint of 2026 AFFO per share guidance.
NETSTREIT Corp. (NYSE:NTST) is a real estate investment trust focused on single-tenant net lease retail properties across the United States.
1. Advanced Micro Devices, Inc. (NASDAQ:AMD)
On April 19, 2026, Stifel raised its price target on Advanced Micro Devices, Inc. (NASDAQ:AMD) to $320 from $280 and maintained a Buy rating on the shares. The firm said its processor coverage sits at “distinctly different points on the AI infrastructure adoption curve,” but noted a shared backdrop where compute demand, both accelerated and general purpose, is running materially ahead of prior forecasts.
On April 15, 2026, Bernstein raised its price target on Advanced Micro Devices, Inc. (NASDAQ:AMD) to $265 from $235 previously and kept a Market Perform rating on the shares, adjusting estimates to reflect stronger server trends, weaker PC assumptions, and a new AI deal with Meta.
Earlier, Wells Fargo added Advanced Micro Devices, Inc. (NASDAQ:AMD) to its Q2 Tactical Ideas List, citing a favorable setup into Q1 results driven by continued strength in EPYC server CPU demand and additional GW-scale AI GPU announcements. The firm also pointed to the July Accelerating AI event as a potential catalyst and maintains an Overweight rating with a $345 price target.
Advanced Micro Devices, Inc. (NASDAQ:AMD) operates as a semiconductor company with segments in Data Center, Client and Gaming, and Embedded.
While we acknowledge the potential of AMD to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than AMD and that has 100x upside potential, check out our report about the cheapest AI stock.
READ NEXT: 8 Best Beginner Stocks to Buy Right Now and 10 Fastest-Growing Financial Stocks to Invest In
Disclosure: None. Insider Monkey focuses on uncovering the best investment ideas of hedge funds and insiders. Please subscribe to our free daily e-newsletter to get the latest investment ideas from hedge funds’ investor letters by entering your email address below.
Hedge Fund Resource Center